Capmatinib in Japanese patients with <i>MET</i> exon 14 skipping–mutated or <i>MET</i>‐amplified advanced NSCLC: GEOMETRY mono‐1 study
Takashi Seto(National Hospital Organization Kyushu Cancer Center), Toyoaki Hida(Saitama International Medical Center), Satoshi Nomura(Novartis (Japan)), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Masayuki Takeda(Kindai University), Takeshi Tajima(Novartis (Japan)), Kadoaki Ohashi(Okayama University Hospital), Keisuke Aoe(National Sanyo Hospital), S. Moizumi(Novartis (Japan))
Cited by 17
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k